患有肥大细胞瘤的狗对替吉诺酯的反应

IF 2.6 2区 农林科学 Journal of Veterinary Internal Medicine Pub Date : 2024-10-17 DOI:10.1111/jvim.17211
Margaret L Musser, Pamela D Jones, Teresa L Goodson, Erin Roof, Chad M Johannes
{"title":"患有肥大细胞瘤的狗对替吉诺酯的反应","authors":"Margaret L Musser, Pamela D Jones, Teresa L Goodson, Erin Roof, Chad M Johannes","doi":"10.1111/jvim.17211","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Information regarding response rate to tigilanol tiglate for mast cell tumors in dogs is limited.</p><p><strong>Objectives: </strong>Report the response rate and durability of tigilanol tiglate intratumoral treatment in dogs with mast cell tumors presented to veterinary oncologists.</p><p><strong>Animals: </strong>One hundred forty-nine dogs; 151 individual tumors.</p><p><strong>Methods: </strong>Multicenter, retrospective survey-based study. Veterinary oncologists subscribed to the American College of Veterinary Internal Medicine (ACVIM) oncology listserv were solicited for information from dogs treated with tigilanol tiglate. An electronic survey was used to collect information at initial treatment, 1 month and 1 year after treatment.</p><p><strong>Results: </strong>Most tumors were cutaneous, occurred on the limbs and were cytologically low grade. Seventy-five percent of dogs achieved a complete response after 1 dose of tigilanol tiglate 1 month after treatment. This response was durable at 1 year in 64% of dogs for which data were available (n = 88). Wound formation, an expectation after treatment, occurred after a median of 7 days (range, 1-91 days), with a median wound area of 4.71 cm<sup>2</sup> (range, 0.09-100 cm<sup>2</sup>). Wounds took a median of 30 days to heal completely (range, 14-154 days). A moderate association between tumor volume and wound size was confirmed.</p><p><strong>Conclusions and clinical importance: </strong>Tigilanol tiglate is an effective local treatment option for mast cell tumors in dogs with a predictable clinical course and response. Because of the unique mode of action and clinical course, client education and careful case selection is necessary before electing tigilanol tiglate for local treatment.</p>","PeriodicalId":17462,"journal":{"name":"Journal of Veterinary Internal Medicine","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Response to tigilanol tiglate in dogs with mast cell tumors.\",\"authors\":\"Margaret L Musser, Pamela D Jones, Teresa L Goodson, Erin Roof, Chad M Johannes\",\"doi\":\"10.1111/jvim.17211\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Information regarding response rate to tigilanol tiglate for mast cell tumors in dogs is limited.</p><p><strong>Objectives: </strong>Report the response rate and durability of tigilanol tiglate intratumoral treatment in dogs with mast cell tumors presented to veterinary oncologists.</p><p><strong>Animals: </strong>One hundred forty-nine dogs; 151 individual tumors.</p><p><strong>Methods: </strong>Multicenter, retrospective survey-based study. Veterinary oncologists subscribed to the American College of Veterinary Internal Medicine (ACVIM) oncology listserv were solicited for information from dogs treated with tigilanol tiglate. An electronic survey was used to collect information at initial treatment, 1 month and 1 year after treatment.</p><p><strong>Results: </strong>Most tumors were cutaneous, occurred on the limbs and were cytologically low grade. Seventy-five percent of dogs achieved a complete response after 1 dose of tigilanol tiglate 1 month after treatment. This response was durable at 1 year in 64% of dogs for which data were available (n = 88). Wound formation, an expectation after treatment, occurred after a median of 7 days (range, 1-91 days), with a median wound area of 4.71 cm<sup>2</sup> (range, 0.09-100 cm<sup>2</sup>). Wounds took a median of 30 days to heal completely (range, 14-154 days). A moderate association between tumor volume and wound size was confirmed.</p><p><strong>Conclusions and clinical importance: </strong>Tigilanol tiglate is an effective local treatment option for mast cell tumors in dogs with a predictable clinical course and response. Because of the unique mode of action and clinical course, client education and careful case selection is necessary before electing tigilanol tiglate for local treatment.</p>\",\"PeriodicalId\":17462,\"journal\":{\"name\":\"Journal of Veterinary Internal Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2024-10-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Veterinary Internal Medicine\",\"FirstCategoryId\":\"97\",\"ListUrlMain\":\"https://doi.org/10.1111/jvim.17211\",\"RegionNum\":2,\"RegionCategory\":\"农林科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Veterinary Internal Medicine","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1111/jvim.17211","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:有关狗对替吉诺酯治疗肥大细胞瘤的反应率的信息有限:报告兽医肿瘤学家接诊的患有肥大细胞瘤的狗接受替吉兰醇替格瑞特瘤内治疗的反应率和持久性:149只狗;151个肿瘤:多中心、回顾性调查研究。向订阅了美国兽医内科学院(ACVIM)肿瘤学列表服务的兽医肿瘤学家征集接受替格瑞洛治疗的狗的信息。研究采用电子调查的方式收集初次治疗、治疗 1 个月和 1 年后的信息:大多数肿瘤为皮肤肿瘤,发生在四肢,细胞学级别较低。治疗 1 个月后,75% 的狗在服用 1 次替吉诺酯后获得了完全应答。在有数据可查的狗中,64%(n = 88)的反应在 1 年后仍能持续。伤口形成是治疗后的预期结果,中位数为 7 天(范围为 1-91 天),中位数伤口面积为 4.71 平方厘米(范围为 0.09-100 平方厘米)。伤口完全愈合的时间中位数为 30 天(范围为 14-154 天)。结论和临床重要性:惕各醇惕各酸酯是治疗犬肥大细胞瘤的一种有效局部治疗方法,其临床疗程和反应可预测。由于其独特的作用方式和临床疗程,在选择替吉兰醇替格瑞酸酯进行局部治疗之前,有必要对客户进行教育并仔细选择病例。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Response to tigilanol tiglate in dogs with mast cell tumors.

Background: Information regarding response rate to tigilanol tiglate for mast cell tumors in dogs is limited.

Objectives: Report the response rate and durability of tigilanol tiglate intratumoral treatment in dogs with mast cell tumors presented to veterinary oncologists.

Animals: One hundred forty-nine dogs; 151 individual tumors.

Methods: Multicenter, retrospective survey-based study. Veterinary oncologists subscribed to the American College of Veterinary Internal Medicine (ACVIM) oncology listserv were solicited for information from dogs treated with tigilanol tiglate. An electronic survey was used to collect information at initial treatment, 1 month and 1 year after treatment.

Results: Most tumors were cutaneous, occurred on the limbs and were cytologically low grade. Seventy-five percent of dogs achieved a complete response after 1 dose of tigilanol tiglate 1 month after treatment. This response was durable at 1 year in 64% of dogs for which data were available (n = 88). Wound formation, an expectation after treatment, occurred after a median of 7 days (range, 1-91 days), with a median wound area of 4.71 cm2 (range, 0.09-100 cm2). Wounds took a median of 30 days to heal completely (range, 14-154 days). A moderate association between tumor volume and wound size was confirmed.

Conclusions and clinical importance: Tigilanol tiglate is an effective local treatment option for mast cell tumors in dogs with a predictable clinical course and response. Because of the unique mode of action and clinical course, client education and careful case selection is necessary before electing tigilanol tiglate for local treatment.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Veterinary Internal Medicine
Journal of Veterinary Internal Medicine Veterinary-General Veterinary
自引率
11.50%
发文量
243
期刊介绍: The mission of the Journal of Veterinary Internal Medicine is to advance veterinary medical knowledge and improve the lives of animals by publication of authoritative scientific articles of animal diseases.
期刊最新文献
Salivary peptidomic profiling of chronic gingivostomatitis in cats by matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry and nanoscale liquid chromatography-tandem mass spectrometry. Effect of phenylbutazone administration on the enteroinsular axis in horses with insulin dysregulation. Retrospective evaluation of risk factors for worsening renal function after angiotensin-converting enzyme inhibitor treatment in dogs. Genotyping and drug susceptibility profiling of Prototheca sp. strains isolated from cases of protothecosis in dogs. Evaluation of laboratory findings indicating pancreatitis in healthy lean, obese, and diabetic cats.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1